Condition
Relapsed AML
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Completed1
Withdrawn1
Terminated1
Active Not Recruiting1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06768476Phase 1Active Not RecruitingPrimary
CART123 + Ruxolitinib in Relapsed/Refractory AML
NCT03560908Phase 1WithdrawnPrimary
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
NCT05226468Phase 1Unknown
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
NCT03516760Phase 1Terminated
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
NCT02675478Phase 1CompletedPrimary
Phase 1 Study of Quizartinib
Showing all 5 trials